Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

The US nursing workforce remains under immense pressure due to stress, burnout, and persistent short staffing, according to a report.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

Infection is a common cause of death in the first year after diagnosis with lower-risk myelodysplastic syndromes, data suggest.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

The FDA has issued a complete response letter to Telix Pharmaceuticals regarding TLX101-CDx for the imaging of gliomas.

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Tepylute is now supplied as a multiple-dose vial containing 100 mg of thiotepa in addition to the previously approved single-dose vial containing 15 mg.